Cole, M. P., Jones, D. T. A. & Todd, I. D. H. 1971. A new antioestrogen agent in late breast cancer. An early appraisal of ICI 46474. British Journal of Cancer 25, 270–275.
CRC Adjuvant Breast Trial Working Party 1988. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer – preliminary analysis. British Journal of Cancer 57, 604–607.
Cummings, F. J., Gray, R., Davis, T. E., Tormey, D. C., Harris, J. E., Falkson, G. G. & Arseneau, J. 1986. Tamoxifen versus placebo: Double-blind adjuvant trial in elderly women with stage II breast cancer. National Cancer Institute Monographs 1, 119–123.
Early Breast Cancer Trialists' Collaborative Group 1988. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. The New England Journal of Medicine 319, 1681–1692.
Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E. R., Plotkin, D., Bowman, D., Sachs, S., Wolter, J., Frelick, R., Desser, R., LiCalzi, N., Geggie, P., Campbell, T., Elias, E. G., Prager, D., Koontz, P., Volk, H., Dimitrov, N., Gardner, B., Lerner, H., Shibata, H. and other NSABP investigators 1981. Treatment of primary breast cancer with chemotherapy and tamoxifen. The New England Journal of Medicine 305, 1–6.
Fisher, B., Redmond, C., Brown, A., Fisher, E. R., Wolmark, N., Bowman, D., Plotkin, D., Wolter, J., Bornstein, R., Legault-Poisson, S., Saffer, E. A. & other NSABP Investigators 1986. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. Journal of Clinical Oncology 4, 459–471.
Fisher, B., Brown, A., Wolmark, N., Redmond, C., Wickerman, D. L., Wittliff, J., Dimitrov, N., Legault-Poisson, S., Schipper, H., Prager, D. and other NSABP investigators 1987. Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel project clinical trial. Annals of Internal Medicine 106, 649–654.
Glick, J. H. 1988. Meeting highlights: Adjuvant therapy for breast cancer. Journal of the National Cancer Institute 80, 471–476.
Goldhirsch, A. & Gelber, R. 1986. Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies. National Cancer Institute Monographs 1, 55–70.
Jackson, I. M. & Lowery, C. 1987. Clinical uses of antioestrogens. In Pharmacology and clinical uses of inhibitors of hormone secretion and action, eds. Furr, B. J. A. & Wakeling, A. E., pp. 87–105. London: Bailliere Tindall.
Mouridsen, H. T., Andersen, A. P., Brincker, H., Dombernowsky, P., Rose, C. & Andersen, K. W. 1986. Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present state of Danish Breast Cancer Cooperative Group Trials. National Cancer Institute Monographs 1, 115–118.
Nolvadex Adjuvant Trial Organisation (NATO) 1988. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. British Journal of Cancer 57, 608–611.
Ribeiro, G. & Swindell, R. 1988. The Christie hospital adjuvant tamoxifen trial – status at 10 years. British Journal of Cancer 57, 601–603.
Scottish Breast Cancer Trials Committee (SBCTC) 1987. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii, 171–175.
Stewart, H. J., Forrest, A. P. M., Gunn, J. M., Hamilton, T., Langlands, A. O., McFadyen, I. J. & Roberts, M. M. 1980. The tamoxifen trial – a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. In Breast cancer. Experimental and clinical aspects, eds Mouridsen, H. T. & Palshof, T. European Journal of Cancer, Supplement 1, 83–88.
Tormey, D. C. 1987. Long-term adjuvant therapy with tamoxifen in breast cancer: How long is long? Annals of Internal Medicine 106, 762–763.